دورية أكاديمية
أعرض في EDS

The Impact of C-3 Side Chain Modifications on Kynurenic Acid: A Behavioral Analysis of Its Analogs in the Motor Domain.

التفاصيل البيبلوغرافية
العنوان: The Impact of C-3 Side Chain Modifications on Kynurenic Acid: A Behavioral Analysis of Its Analogs in the Motor Domain.
المؤلفون: Martos D; HUN-REN-SZTE Neuroscience Research Group, Hungarian Research Network, University of Szeged, Danube Neuroscience Research Laboratory, Tisza Lajos krt. 113, H-6725 Szeged, Hungary., Lőrinczi B; Institute of Pharmaceutical Chemistry and HUN-REN-SZTE Stereochemistry Research Group, University of Szeged, Eötvös u. 6, H-6720 Szeged, Hungary., Szatmári I; Institute of Pharmaceutical Chemistry and HUN-REN-SZTE Stereochemistry Research Group, University of Szeged, Eötvös u. 6, H-6720 Szeged, Hungary., Vécsei L; HUN-REN-SZTE Neuroscience Research Group, Hungarian Research Network, University of Szeged, Danube Neuroscience Research Laboratory, Tisza Lajos krt. 113, H-6725 Szeged, Hungary.; Department of Neurology, Albert Szent-Györgyi Medical School, University of Szeged, Semmelweis u. 6, H-6725 Szeged, Hungary., Tanaka M; HUN-REN-SZTE Neuroscience Research Group, Hungarian Research Network, University of Szeged, Danube Neuroscience Research Laboratory, Tisza Lajos krt. 113, H-6725 Szeged, Hungary.
المصدر: International journal of molecular sciences [Int J Mol Sci] 2024 Mar 16; Vol. 25 (6). Date of Electronic Publication: 2024 Mar 16.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI, [2000-
مواضيع طبية MeSH: Kynurenic Acid* , Neuroprotective Agents*/chemistry, Blood-Brain Barrier ; Drug Delivery Systems ; Open Field Test
مستخلص: The central nervous system (CNS) is the final frontier in drug delivery because of the blood-brain barrier (BBB), which poses significant barriers to the access of most drugs to their targets. Kynurenic acid (KYNA), a tryptophan (Trp) metabolite, plays an important role in behavioral functions, and abnormal KYNA levels have been observed in neuropsychiatric conditions. The current challenge lies in delivering KYNA to the CNS owing to its polar side chain. Recently, C-3 side chain-modified KYNA analogs have been shown to cross the BBB; however, it is unclear whether they retain the biological functions of the parent molecule. This study examined the impact of KYNA analogs, specifically, SZR-72, SZR-104, and the newly developed SZRG-21, on behavior. The analogs were administered intracerebroventricularly (i.c.v.), and their effects on the motor domain were compared with those of KYNA. Specifically, open-field (OF) and rotarod (RR) tests were employed to assess motor activity and skills. SZR-104 increased horizontal exploratory activity in the OF test at a dose of 0.04 μmol/4 μL, while SZR-72 decreased vertical activity at doses of 0.04 and 0.1 μmol/4 μL. In the RR test, however, neither KYNA nor its analogs showed any significant differences in motor skills at either dose. Side chain modification affects affective motor performance and exploratory behavior, as the results show for the first time. In this study, we showed that KYNA analogs alter emotional components such as motor-associated curiosity and emotions. Consequently, drug design necessitates the development of precise strategies to traverse the BBB while paying close attention to modifications in their effects on behavior.
References: Handb Clin Neurol. 2013;117:59-77. (PMID: 24095116)
Biomedicines. 2023 May 17;11(5):. (PMID: 37239136)
Front Mol Neurosci. 2023 Jul 28;16:1217090. (PMID: 37575966)
Brain Res. 1980 Jun 16;192(1):17-28. (PMID: 6103738)
Neural Plast. 2021 Dec 6;2021:6564585. (PMID: 34912450)
Biomedicines. 2022 Aug 05;10(8):. (PMID: 36009445)
Int J Mol Sci. 2024 Feb 27;25(5):. (PMID: 38473973)
J Vis Exp. 2018 Jan 23;(131):. (PMID: 29443024)
Biotechnol Genet Eng Rev. 2021 Oct;37(2):105-153. (PMID: 34678130)
Front Psychiatry. 2023 May 19;14:1188603. (PMID: 37275974)
Cells. 2022 Aug 21;11(16):. (PMID: 36010683)
Contemp Top Lab Anim Sci. 2003 Nov;42(6):49. (PMID: 14615963)
Crit Rev Food Sci Nutr. 2022;62(31):8793-8811. (PMID: 34085885)
J Psychopharmacol. 2007 Mar;21(2):134-5. (PMID: 17329288)
Rev Neurosci. 2022 Sep 05;34(3):313-324. (PMID: 36054612)
J Pharmacol Exp Ther. 2017 Jan;360(1):201-205. (PMID: 27754930)
J Neural Transm (Vienna). 2012 Feb;119(2):165-72. (PMID: 21818601)
Brain Sci. 2022 May 27;12(6):. (PMID: 35741578)
Curr Opin Pharmacol. 2004 Feb;4(1):12-7. (PMID: 15018833)
Behav Pharmacol. 2019 Apr;30(2 and 3-Spec Issue):163-186. (PMID: 30844963)
Neuropharmacology. 2017 Jan;112(Pt B):297-306. (PMID: 27245499)
Aust N Z J Psychiatry. 2021 May;55(5):451-462. (PMID: 33673739)
Front Immunol. 2022 Sep 08;13:985378. (PMID: 36159806)
Am J Physiol Cell Physiol. 2020 May 1;318(5):C818-C830. (PMID: 32208989)
Int J Mol Sci. 2023 Oct 30;24(21):. (PMID: 37958722)
Curr Med Chem. 2015;22(24):2902-18. (PMID: 26051411)
Front Immunol. 2019 Oct 30;10:2565. (PMID: 31736978)
J Neurol Sci. 2012 Dec 15;323(1-2):1-8. (PMID: 22939820)
Front Psychiatry. 2022 Sep 29;13:932635. (PMID: 36245880)
Biomedicines. 2023 Nov 27;11(12):. (PMID: 38137376)
Int J Tryptophan Res. 2013 Sep 04;6:47-55. (PMID: 24049450)
Biol Psychiatry. 2016 Dec 1;80(11):878-887. (PMID: 27105831)
Biomolecules. 2021 Jun 16;11(6):. (PMID: 34208760)
Biomedicines. 2021 Sep 22;9(10):. (PMID: 34680410)
Biomedicines. 2021 Apr 08;9(4):. (PMID: 33917863)
ACS Chem Neurosci. 2017 Dec 20;8(12):2667-2675. (PMID: 28825789)
Pharmacol Ther. 2004 Oct;104(1):29-45. (PMID: 15500907)
Mol Psychiatry. 2021 Aug;26(8):4158-4178. (PMID: 33230205)
CNS Neurol Disord Drug Targets. 2007 Dec;6(6):398-410. (PMID: 18220779)
Front Psychiatry. 2023 Jul 10;14:1219592. (PMID: 37492064)
Am J Transl Res. 2016 Feb 15;8(2):749-64. (PMID: 27158367)
Biol Psychiatry. 2017 May 15;81(10):886-897. (PMID: 27449797)
Psychol Bull. 1976 May;83(3):482-504. (PMID: 17582919)
Expert Rev Mol Med. 2006 Aug 31;8(20):1-27. (PMID: 16942634)
Curr Neuropharmacol. 2008 Sep;6(3):179-92. (PMID: 19506719)
Brain Behav Immun Health. 2019 Dec 27;2:100034. (PMID: 38377429)
Mol Psychiatry. 2020 Nov;25(11):2860-2872. (PMID: 30940904)
Adv Clin Exp Med. 2023 Jun;32(6):607-612. (PMID: 37278106)
Biomedicines. 2022 Apr 05;10(4):. (PMID: 35453599)
Dialogues Clin Neurosci. 2009;11(3):319-32. (PMID: 19877499)
Biomedicines. 2023 Oct 21;11(10):. (PMID: 37893229)
Front Immunol. 2019 Jun 21;10:1406. (PMID: 31316502)
Cells. 2023 May 25;12(11):. (PMID: 37296599)
Br J Pharmacol. 2006 Jan;147 Suppl 1:S232-40. (PMID: 16402109)
Biomedicines. 2021 Jun 02;9(6):. (PMID: 34199476)
Cells. 2023 Nov 17;12(22):. (PMID: 37998384)
Front Psychiatry. 2023 Jan 16;13:1068054. (PMID: 36727088)
Methods Mol Biol. 2020;2066:171-194. (PMID: 31512217)
J Neurochem. 1990 May;54(5):1576-83. (PMID: 1691278)
Curr Pharm Des. 2020;26(13):1466-1485. (PMID: 32091330)
Eur J Med Chem. 2014 Jul 23;82:385-93. (PMID: 24929289)
Biomedicines. 2023 Aug 08;11(8):. (PMID: 37626716)
Neuropharmacology. 2017 Jan;112(Pt B):331-345. (PMID: 26970015)
J Nat Prod. 2020 Jul 24;83(7):2145-2154. (PMID: 32631063)
Front Behav Neurosci. 2022 Sep 30;16:998714. (PMID: 36248028)
Int J Pharm. 2023 Apr 5;636:122759. (PMID: 36801479)
Expert Opin Drug Deliv. 2009 Mar;6(3):211-25. (PMID: 19290842)
Biomedicines. 2022 May 09;10(5):. (PMID: 35625833)
Int J Comput Biol Drug Des. 2013;6(1-2):146-56. (PMID: 23428480)
Front Psychiatry. 2023 May 25;14:1205126. (PMID: 37304446)
Mol Biol Rep. 2023 Dec;50(12):10409-10425. (PMID: 37848760)
Front Behav Neurosci. 2022 Jul 22;16:946263. (PMID: 35941933)
Biol Psychiatry. 2022 Mar 1;91(5):449-458. (PMID: 34266671)
Pharmaceutics. 2021 Jan 05;13(1):. (PMID: 33466551)
J Mol Neurosci. 2007 Sep;33(1):32-41. (PMID: 17901543)
Front Psychiatry. 2022 Mar 09;13:847618. (PMID: 35356711)
ScientificWorldJournal. 2012;2012:267120. (PMID: 22654580)
Biol Psychiatry. 2016 Sep 15;80(6):457-468. (PMID: 27062563)
Front Biosci (Landmark Ed). 2015 Jun 01;20(7):1116-43. (PMID: 25961549)
Drug Deliv. 2019 Dec;26(1):551-565. (PMID: 31928355)
Neurobiol Dis. 2010 Jan;37(1):48-57. (PMID: 19664710)
Front Immunol. 2020 Jul 16;11:1497. (PMID: 32765517)
Trends Neurosci. 2022 Jul;45(7):504-506. (PMID: 35577621)
Clin Psychopharmacol Neurosci. 2020 Nov 30;18(4):507-526. (PMID: 33124585)
Front Immunol. 2021 Oct 21;12:702764. (PMID: 34745090)
J Med Chem. 2021 Sep 23;64(18):13152-13173. (PMID: 34505508)
Front Psychiatry. 2022 Jun 28;13:913303. (PMID: 35836656)
Biomedicines. 2021 Jun 23;9(7):. (PMID: 34201608)
Biomedicines. 2021 Jun 28;9(7):. (PMID: 34203450)
Neuropharmacology. 1990 Mar;29(3):291-3. (PMID: 2109276)
J Inherit Metab Dis. 2013 May;36(3):437-49. (PMID: 23609350)
Biomedicines. 2024 Feb 17;12(2):. (PMID: 38398050)
J Affect Disord. 2021 May 1;286:78-79. (PMID: 33714173)
Int J Tryptophan Res. 2019 Jun 19;12:1178646919852996. (PMID: 31258331)
Mol Psychiatry. 2022 Feb;27(2):784-786. (PMID: 34667263)
Neurosci Biobehav Rev. 2021 Aug;127:334-352. (PMID: 33964307)
J Neural Transm (Vienna). 2012 Feb;119(2):151-4. (PMID: 22231843)
Int J Mol Sci. 2022 Jan 19;23(3):. (PMID: 35163002)
Biomedicines. 2022 Apr 22;10(5):. (PMID: 35625710)
Ital J Pediatr. 2018 Nov 16;44(Suppl 2):131. (PMID: 30442184)
Front Psychiatry. 2023 Mar 16;14:1149663. (PMID: 37009125)
Adv Clin Exp Med. 2021 Aug;30(8):775-778. (PMID: 34418336)
Biomedicines. 2023 Jun 25;11(7):. (PMID: 37509462)
Biomed Res Int. 2014;2014:869269. (PMID: 25136634)
Ann N Y Acad Sci. 2007 Dec;1122:35-49. (PMID: 18077563)
Front Psychiatry. 2022 Oct 17;13:1027907. (PMID: 36325532)
Front Immunol. 2021 Aug 12;12:717157. (PMID: 34475875)
Biomedicines. 2022 Oct 13;10(10):. (PMID: 36289824)
Semin Cell Dev Biol. 2015 Apr;40:134-41. (PMID: 25773161)
Int J Mol Sci. 2023 Feb 18;24(4):. (PMID: 36835524)
Cells. 2021 Jun 19;10(6):. (PMID: 34205235)
Acc Chem Res. 2017 Aug 15;50(8):1847-1854. (PMID: 28715199)
Molecules. 2020 Jan 28;25(3):. (PMID: 32012948)
Annu Rev Pharmacol Toxicol. 2003;43:629-56. (PMID: 12415123)
Neurochem Res. 2022 Jun;47(6):1459-1476. (PMID: 35133568)
J Pharmacol Exp Ther. 2006 Oct;319(1):308-16. (PMID: 16803861)
Antioxidants (Basel). 2022 Mar 09;11(3):. (PMID: 35326176)
J Enzyme Inhib Med Chem. 2023 Dec;38(1):2225800. (PMID: 37381707)
Nat Rev Neurosci. 2012 Jul;13(7):465-77. (PMID: 22678511)
CNS Neurosci Ther. 2022 Jan;28(1):19-35. (PMID: 34862742)
Front Psychiatry. 2023 Apr 27;14:1192562. (PMID: 37181906)
Expert Opin Ther Targets. 2018 Oct;22(10):849-867. (PMID: 30223691)
Acta Psychiatr Scand. 2023 Nov;148(5):463-466. (PMID: 37548028)
J Pineal Res. 2008 Oct;45(3):235-46. (PMID: 18341517)
Trends Mol Med. 2021 Oct;27(10):946-954. (PMID: 34373202)
Angew Chem Int Ed Engl. 2018 Sep 10;57(37):11868-11881. (PMID: 29740917)
Biomedicines. 2021 Jun 25;9(7):. (PMID: 34202246)
Biomedicines. 2022 Apr 20;10(5):. (PMID: 35625684)
J Med Food. 2022 Aug;25(8):797-806. (PMID: 35353606)
Brain Behav Immun. 2016 Mar;53:39-48. (PMID: 26546831)
Neuropharmacology. 2009 Sep;57(3):242-9. (PMID: 19523966)
Curr Biol. 2020 Sep 21;30(18):3672-3679.e4. (PMID: 32735813)
J Neurosci Methods. 2023 Sep 1;397:109940. (PMID: 37544382)
J Neural Transm (Vienna). 1999;106(2):165-81. (PMID: 10226937)
Bioorg Med Chem Lett. 2008 Jan 1;18(1):205-9. (PMID: 18024028)
Front Biosci (Landmark Ed). 2022 Sep 27;27(9):265. (PMID: 36224022)
Neuropharmacology. 2017 Jan;112(Pt B):373-388. (PMID: 26995730)
J Neural Transm (Vienna). 2008 Aug;115(8):1087-91. (PMID: 18446262)
Exp Gerontol. 2020 Jan;129:110770. (PMID: 31704347)
Curr Top Behav Neurosci. 2022;56:261-285. (PMID: 35546382)
J Med Chem. 2010 Mar 25;53(6):2354-63. (PMID: 20170117)
Eur J Pharmacol. 1979 Nov 16;59(3-4):169-79. (PMID: 575093)
J Mol Med (Berl). 2013 Jun;91(6):705-13. (PMID: 23636512)
Front Neurosci. 2023 Jan 30;17:1098573. (PMID: 36793538)
Biomedicines. 2024 Jan 17;12(1):. (PMID: 38255316)
Expert Opin Drug Deliv. 2009 Aug;6(8):771-84. (PMID: 19566446)
Biomedicines. 2023 Jun 07;11(6):. (PMID: 37371747)
Biomedicines. 2020 Oct 12;8(10):. (PMID: 33053739)
Front Cell Infect Microbiol. 2018 Feb 06;8:13. (PMID: 29468141)
Int J Mol Sci. 2024 Jan 04;25(1):. (PMID: 38203830)
Int J Tryptophan Res. 2009;2:1-19. (PMID: 22084578)
Mol Cell Neurosci. 2011 Dec;48(4):308-20. (PMID: 21600287)
European J Org Chem. 2016 Dec;2016(35):5799-5802. (PMID: 28111524)
Br J Pharmacol. 2013 Jul;169(6):1211-27. (PMID: 23647169)
Biomedicines. 2023 Dec 18;11(12):. (PMID: 38137565)
Auton Neurosci. 2022 Jan 31;238:102948. (PMID: 35149372)
Curr Pharm Des. 2014;20(10):1422-49. (PMID: 23789948)
Expert Opin Pharmacother. 2021 Jul;22(10):1221-1225. (PMID: 33843394)
Neurosci Biobehav Rev. 2023 Jun;149:105163. (PMID: 37028578)
Front Behav Neurosci. 2023 Aug 15;17:1268156. (PMID: 37654442)
Biomedicines. 2023 Mar 20;11(3):. (PMID: 36979924)
J Control Release. 2016 Oct 28;240:251-266. (PMID: 26724368)
Neurosci Lett. 2020 Jan 1;714:134576. (PMID: 31654722)
J Neurochem. 2006 Mar;96(6):1636-47. (PMID: 16476080)
Nat Rev Drug Discov. 2019 May;18(5):379-401. (PMID: 30760888)
Neuropsychopharmacology. 2015 Jan;40(2):463-71. (PMID: 25074636)
Int J Mol Sci. 2022 Jun 20;23(12):. (PMID: 35743291)
Neuropharmacology. 2017 Jan;112(Pt B):264-274. (PMID: 26767951)
Biomedicines. 2021 Mar 27;9(4):. (PMID: 33801765)
Antioxidants (Basel). 2021 Nov 05;10(11):. (PMID: 34829646)
Molecules. 2020 Jan 23;25(3):. (PMID: 31979316)
Aging Dis. 2023 Jun 1;14(3):858-878. (PMID: 37191427)
Biomedicines. 2023 May 19;11(5):. (PMID: 37239151)
Curr Alzheimer Res. 2015;12(5):462-80. (PMID: 26017558)
Neurosci Biobehav Rev. 2022 Jun;137:104659. (PMID: 35405181)
Neuropharmacology. 2009 Sep;57(4):425-9. (PMID: 19580819)
Biomedicines. 2021 Jul 26;9(8):. (PMID: 34440101)
Biomedicines. 2023 Dec 12;11(12):. (PMID: 38137507)
J Neural Transm (Vienna). 2017 Mar;124(3):369-377. (PMID: 27878585)
Pharmacol Rep. 2020 Apr;72(2):449-455. (PMID: 32162182)
Biomedicines. 2023 Nov 22;11(12):. (PMID: 38137335)
Curr Pharm Des. 2016;22(8):955-62. (PMID: 26714730)
Adv Clin Exp Med. 2023 May;32(5):505-509. (PMID: 37212773)
J Neurol Sci. 2017 May 15;376:63-70. (PMID: 28431630)
Int J Mol Sci. 2023 Mar 21;24(6):. (PMID: 36983000)
Biomedicines. 2024 Jan 13;12(1):. (PMID: 38255283)
Int J Mol Sci. 2020 Dec 08;21(24):. (PMID: 33302404)
Front Psychiatry. 2022 Nov 09;13:1054380. (PMID: 36440395)
Exp Eye Res. 1977;25 Suppl:177-90. (PMID: 338316)
J Neurosci. 2020 Oct 28;40(44):8491-8500. (PMID: 33020217)
Int J Mol Sci. 2020 Mar 31;21(7):. (PMID: 32244523)
Front Psychiatry. 2022 Jun 24;13:927075. (PMID: 35815007)
Brain Sci. 2023 Aug 12;13(8):. (PMID: 37626553)
Neural Plast. 2016;2016:7215684. (PMID: 26819772)
Cortex. 2024 Feb;171:235-246. (PMID: 38096756)
Front Immunol. 2018 Jan 10;8:1957. (PMID: 29379504)
Int J Mol Sci. 2020 Feb 21;21(4):. (PMID: 32098023)
Int J Mol Sci. 2020 Nov 20;21(22):. (PMID: 33233627)
Annu Rev Anim Biosci. 2017 Feb 8;5:371-389. (PMID: 28199172)
Science. 2017 Jul 28;357(6349):. (PMID: 28751584)
Biomedicines. 2021 Nov 19;9(11):. (PMID: 34829952)
J Affect Disord. 2020 Apr 15;267:103-106. (PMID: 32063560)
Behav Res Ther. 2021 Nov;146:103963. (PMID: 34530318)
Peptides. 2001 Dec;22(12):2329-43. (PMID: 11786210)
Front Psychiatry. 2023 May 19;14:1184797. (PMID: 37275967)
Pharmacol Ther. 2021 Jul;223:107807. (PMID: 33476641)
Curr Med Chem. 2007;14(11):1199-206. (PMID: 17504140)
Cells. 2021 Jun 26;10(7):. (PMID: 34206739)
Biomedicines. 2023 Dec 09;11(12):. (PMID: 38137487)
Complex Psychiatry. 2021 Aug;7(1-2):19-33. (PMID: 35141700)
J Membr Biol. 2015 Aug;248(4):651-69. (PMID: 25675910)
Biomedicines. 2023 Mar 27;11(4):. (PMID: 37189642)
Trends Cogn Sci. 2017 May;21(5):357-371. (PMID: 28363681)
Prog Neuropsychopharmacol Biol Psychiatry. 2009 Feb 1;33(1):45-8. (PMID: 18996162)
J Consult Clin Psychol. 1992 Jun;60(3):329-38. (PMID: 1619087)
Biomedicines. 2021 Jul 06;9(7):. (PMID: 34356846)
FEBS J. 2012 Apr;279(8):1375-85. (PMID: 22404766)
Biomedicines. 2022 Feb 14;10(2):. (PMID: 35203655)
Neurosci Lett. 2006 Jul 10;402(1-2):108-12. (PMID: 16644124)
Front Cell Neurosci. 2021 Sep 13;15:661838. (PMID: 34588955)
Biomedicines. 2023 Jul 18;11(7):. (PMID: 37509661)
J Neural Transm (Vienna). 2017 Jan;124(1):99-112. (PMID: 27629500)
معلومات مُعتمدة: NKFIH K138125 National Research, Development, and Innovation Office; 2022/5S729 SZTE SZAOK-KKA; 0 HUN-REN Hungarian Research Network; TKP-2021-EGA-32 Ministry of Human Capacities, Hungary grant; 166 ÚNKP-22-4-SZTE
فهرسة مساهمة: Keywords: analogs; blood–brain barrier; drug delivery; drug design; emotions; exploratory behavior; kynurenic acid; motor skills; neuropsychiatry; tryptophan
المشرفين على المادة: H030S2S85J (Kynurenic Acid)
0 (Neuroprotective Agents)
تواريخ الأحداث: Date Created: 20240328 Date Completed: 20240329 Latest Revision: 20240330
رمز التحديث: 20240330
مُعرف محوري في PubMed: PMC10970565
DOI: 10.3390/ijms25063394
PMID: 38542368
قاعدة البيانات: MEDLINE
الوصف
تدمد:1422-0067
DOI:10.3390/ijms25063394